Allergy Shots For Hives: SCIT Is Not First-Line — Xolair Is
No — subcutaneous immunotherapy (SCIT) is not the first-line treatment for chronic urticaria (chronic hives). The FDA-approved targeted therapy for chronic spontaneous urticaria (CSU) is omalizumab (Xolair), an anti-IgE monoclonal antibody approved in 2014. SCIT is NOT indicated for CSU per Cox 2011 PP3. Exception: venom immunotherapy (VIT) IS indicated for hives from Hymenoptera sting anaphylaxis.
6 peer-reviewed sources
Allergy shots (SCIT) are not for chronic hives. The FDA-approved treatment for chronic spontaneous urticaria is Xolair (omalizumab), not SCIT. Exception: venom shots (VIT) work for bee/wasp-sting-induced hives.
The essentials
If you are searching "allergy shots for hives," you are most likely in the wrong treatment category. Subcutaneous immunotherapy (SCIT) — the 3-to-5-year course of allergen-extract injections codified by Cox L et al. (J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55, DOI 10.1016/j.jaci.2010.09.034, AAAAI/ACAAI/JCAAI Practice Parameter Third Update) — is indicated for allergic rhinitis, allergic conjunctivitis, allergic asthma, and Hymenoptera venom hypersensitivity. SCIT is NOT indicated for chronic urticaria.
The FDA-approved targeted therapy for chronic spontaneous urticaria (CSU) is omalizumab (Xolair), an anti-IgE monoclonal antibody (IgG1-kappa). Xolair binds free IgE in the circulation, preventing IgE from attaching to mast cell surface FcεRI receptors — disrupting the trigger for mast cell degranulation and histamine release that drives hive formation. Xolair was FDA-approved in 2014 for CSU in patients aged 12 and older who remain symptomatic on H1-antihistamines. Dosing: 150 mg or 300 mg subcutaneous every 4 weeks.
The search phrase "allergy shots for hives" conflates two distinct patient populations:
1. Acute urticaria from a known allergen (food, medication, latex, environmental contact) — managed with identification of the trigger, avoidance, and H1 antihistamines. SCIT is NOT appropriate here. The appropriate next step is allergen identification and avoidance, not immunotherapy for the urticaria itself.
2. Chronic spontaneous urticaria (CSU) — defined as recurrent hives lasting ≥6 weeks without an identified trigger. CSU affects approximately 0.5-1% of the population at any given time; approximately 1-in-5 people develop hives lasting ≥6 weeks at some point in their life. The treatment pathway: (1) second-generation H1 antihistamines (cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine, bilastine) at standard dose; (2) up-dose H1 antihistamines up to 4× standard dose per AAAAI/EAACI joint guidelines; (3) omalizumab (Xolair) for patients who remain symptomatic. SCIT is not in this pathway.
Curex offers at-home IgE testing with board-certified allergist review — useful for ruling out specific allergen triggers in acute urticaria but NOT diagnostic of chronic spontaneous urticaria, which is by definition triggerless and managed with antihistamines and Xolair rather than SCIT or sublingual immunotherapy.
The critical carve-out: venom immunotherapy (VIT) IS indicated for hives that arise in the context of a Hymenoptera (bee, wasp, hornet, yellow jacket) sting systemic reaction. When a bee sting produces generalized urticaria, angioedema, or anaphylaxis — that is venom-triggered IgE-mediated systemic reaction, and VIT is the gold-standard treatment. The Cochrane VIT meta-analysis (Boyle RJ et al., Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions in 2.7% of treated versus 39.8% of untreated patients (RR 0.10, 95% CI 0.03-0.28). Golden DBK et al. (JACI 2005) report VIT prevents systemic sting reactions in >95% of treated patients. This is the one scenario where "allergy shots for hives" is accurate — and it is specifically venom shots, not aeroallergen SCIT.
Other CSU therapies in development or occasional clinical use: cyclosporine (off-label immunosuppressant for refractory CSU); dupilumab (Dupixent, anti-IL-4Rα — emerging evidence for CSU). Bonadonna 2013 JACI noted that elevated baseline tryptase warrants a mast cell disorder workup, particularly relevant for VIT relapse risk assessment.
Curex's at-home allergy shot program (SCIT) at $129/month addresses aeroallergen IgE sensitization — allergic rhinitis and similar indications. It is not a treatment for chronic spontaneous urticaria. Patients with CSU should pursue the antihistamine + Xolair pathway with their allergist or dermatologist, separate from any SCIT evaluation.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
Will allergy shots help my chronic hives?
For chronic spontaneous urticaria (hives lasting ≥6 weeks without identified trigger), allergy shots (SCIT) are not the appropriate treatment. Cox L et al. (J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55) list chronic urticaria as a non-indication for SCIT. The FDA-approved targeted therapy for CSU in patients aged 12 and older who remain symptomatic on H1-antihistamines is omalizumab (Xolair). If your hives arise specifically from a bee or wasp sting and you have experienced a systemic reaction (generalized hives, throat tightness, difficulty breathing), that scenario is different — venom immunotherapy (VIT) IS indicated and is highly effective. The first step is evaluation by a board-certified allergist who can distinguish acute IgE-triggered urticaria, CSU, and venom-triggered systemic reactions.
What is Xolair and how is it different from allergy shots?
Xolair (omalizumab) is an anti-IgE monoclonal antibody given as a subcutaneous injection every 4 weeks. It works by binding free IgE in the bloodstream, preventing IgE from attaching to mast cell receptors and triggering degranulation and histamine release. Allergy shots (SCIT) inject specific allergen extracts to retrain the immune system toward tolerance — they are allergen-specific and work through a different mechanism (regulatory T-cell expansion, IgG4 class-switching). Xolair is FDA-approved for moderate-to-severe persistent asthma (in patients with IgE-mediated asthma ≥6 years), chronic spontaneous urticaria (CSU, ≥12 years), and multi-food allergy reaction prevention (February 16, 2024, ages 1-55). SCIT is not approved for CSU. Both are injectable allergy-related therapies, but they are different product classes with different indications.
What is the treatment pathway for chronic hives?
The guideline-based treatment pathway for chronic spontaneous urticaria (CSU) per AAAAI/EAACI joint guidelines: Step 1 — second-generation H1 antihistamines (cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine) at standard once-daily dosing. Step 2 — up-dose second-generation H1 antihistamines to up to 4× the standard dose. Step 3 — add omalizumab (Xolair) 150 mg or 300 mg SC every 4 weeks for patients who remain symptomatic on up-dosed antihistamines. Cyclosporine (off-label immunosuppressant) and dupilumab (emerging evidence) are used in refractory cases. Allergy shots (SCIT) are not in this pathway. A board-certified allergist or dermatologist familiar with CSU management should guide the evaluation and treatment selection.
Do allergy shots work for hives from bee or wasp stings?
Yes — for hives (and anaphylaxis) arising from Hymenoptera (bee, wasp, hornet, yellow jacket) stings, venom immunotherapy (VIT) is the appropriate and highly effective treatment. This is the one scenario where "allergy shots for hives" is accurate — but it refers specifically to venom shots, not aeroallergen SCIT. The Cochrane VIT meta-analysis (Boyle RJ et al., Cochrane 2012, PMID 23076950) found subsequent systemic sting reactions in 2.7% of VIT-treated patients versus 39.8% of untreated patients (RR 0.10, 95% CI 0.03-0.28). Golden DBK et al. (JACI 2005) report >95% prevention of systemic sting reactions with VIT. VIT is indicated in patients who have had systemic allergic reactions (generalized hives, angioedema, or anaphylaxis) to Hymenoptera stings and have positive venom skin or IgE testing.
Can allergy shots cause hives?
Yes — allergy shots can cause hives as a manifestation of a systemic reaction. Generalized urticaria (hives beyond the injection site) is classified as a WAO grade 2 systemic reaction (Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G, JACI 2010). Systemic reactions occur in approximately 0.1% of injection visits (Epstein TG et al., Ann Allergy Asthma Immunol PMID 23535092). Hives from an allergy shot that appear beyond the injection arm during the mandatory 30-minute observation window should be reported to your care team immediately — they may be managed with antihistamines or epinephrine depending on severity. The 30-minute observation period exists specifically to detect and treat these reactions before they progress. If hives appear after your 30-minute observation window ends, contact the allergist or seek emergency care if any accompanying systemic symptoms are present.
Is there any allergy shot that treats hives directly?
The only injection-based therapy with an established FDA-approved indication for chronic urticaria is omalizumab (Xolair) — an anti-IgE biologic, not an allergen extract. Xolair was FDA-approved in 2014 for chronic spontaneous urticaria (CSU) in patients aged 12 and older who remain symptomatic on H1-antihistamines. SCIT (allergen-extract immunotherapy) does not have an approved or guideline-supported indication for chronic urticaria of any type except the venom-induced systemic reaction scenario described above. Dupilumab (Dupixent, anti-IL-4Rα) is emerging in the CSU literature but does not have a current FDA approval for CSU specifically. If you are seeking an injection treatment for chronic hives, the conversation with your allergist or dermatologist should center on Xolair, not SCIT.
Can allergy testing help diagnose the cause of my hives?
Allergy testing can help identify specific allergen triggers for acute urticaria (IgE-mediated reactions to a food, medication, or environmental contact agent producing hives within minutes to an hour of exposure). For chronic spontaneous urticaria — by definition occurring for ≥6 weeks without an identified trigger — allergy testing does not typically reveal a causal allergen because CSU is not driven by IgE sensitization to external allergens in most cases. Testing may be useful to exclude an IgE-mediated component and to rule in or out coexisting allergic rhinitis or asthma. If venom sensitization is suspected (history of systemic sting reactions), venom skin testing or specific IgE is diagnostically relevant and guides VIT candidacy. A board-certified allergist will direct the testing workup based on your clinical presentation.
Related Articles
Allergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Shot for Dog Allergies | Curex Human SCIT Guide
Yes, there is an allergy shot for humans allergic to dogs — but dog SCIT evidence is 'poor and conflicting.' 16.5% of patients may skip shots if Can f 5-monosensitized.
Read moreShot for Pollen Allergy: SCIT Guide | Curex
Shot for pollen allergy: SCIT with Cochrane SMD −0.73 (51 RCTs). Durham 1999: 3-yr grass course → 3+ yr remission. 7 FDA-standardized extracts listed.
Read moreAllergy Shots Treatment: Evidence & Schedule | Curex
Allergy shots treatment is 3-5 yr SCIT: Cochrane SMD −0.73, NNT 3 for asthma, 1 fatality per 2.5M injections. Not for chronic urticaria or food allergy. Full guide.
Read morePollen Allergy Shots: Efficacy & Evidence | Curex Guide
Pollen SCIT has the strongest immunotherapy RCT base: grass 49% symptom reduction (Walker 2001), ragweed NEJM 1996, birch 40% (Bødtger 2002). Full regional map inside.
Read moreAllergy Shot Test: Skin Testing vs SCIT | Curex Guide
Allergy shot test = skin prick testing (CPT 95004, diagnostic). NOT the same as a SCIT shot (CPT 95117). HOPD test panels billed $24,400–$48,329.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.